CTLA4 and autoimmune disease: ,11 Many established autoimmune-disease drug targets, such as TNF blockers, IL23/IL12 antagonists, and CTLA4 agonists, have either prospectively or retrospectively been shown to reside in GWAS loci of autoimmune diseases.1